A wine storage apparatus is provided. The wine storage apparatus includes a housing, a door configured to open and close the housing and including a display, a rack provided inside the housing and configured to hold a bottle of wine, a sensor configured to obtain information about whether a bottle of wine is stored on the rack, and a processor configured to identify whether the bottle of wine is stored on the rack based on the information, and control the display to display guide information of the bottle of wine based on an identification result.

Systems and methods may support build direction-based partitioning for construction of a physical object through additive manufacturing. In some implementations, a system may access a surface mesh representative of a 3D object and an initial build direction for construction of the object using additive manufacturing. The system may partition the surface mesh into an initial buildable segment and a non-buildable segment based on the initial build direction. The system may iteratively determine subsequent build directions and partition off subsequent buildable segments from the unbuildable segment until no portion of the non-buildable segment remains. The determined buildable segments and correlated build directions may be provided to a multi-axis 3D printer for construction of the represented 3D object through additive manufacturing.

A wine storage apparatus is provided. The wine storage apparatus includes a housing, a door configured to open and close the housing and including a display, a rack provided inside the housing and configured to hold a bottle of wine, a sensor configured to obtain information about whether a bottle of wine is stored on the rack, and a processor configured to identify whether the bottle of wine is stored on the rack based on the information, and control the display to display guide information of the bottle of wine based on an identification result.

Presented herein are systems and methods of producing universal and/or off-the-shelf CAR-T compositions suitable for cancer therapy to be administered to one or more individuals. A CAR-T composition is a composition comprising one or more types of chimeric antigen receptor T cells (CAR-T). The iPSCs and/or cell lines, and any iPSC-derived CAR-T compositions derived therefrom, are identified as compatible with one or more individuals using an identification of a cell type indicative of compatibility (e.g., HLA match and/or ABO blood match and/or RHD blood match). The compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a donor. The retrieved compatible cells are then used to derive iPSC-derived CAR-T compositions, wherein the derived compositions are suitable for therapy of one or more individuals.

Systems and methods may support build direction-based partitioning for construction of a physical object through additive manufacturing. In some implementations, a system may access a surface mesh representative of a 3D object and an initial build direction for construction of the object using additive manufacturing. The system may partition the surface mesh into an initial buildable segment and a non-buildable segment based on the initial build direction. The system may iteratively determine subsequent build directions and partition off subsequent buildable segments from the unbuildable segment until no portion of the non-buildable segment remains. The determined buildable segments and correlated build directions may be provided to a multi-axis 3D printer for construction of the represented 3D object through additive manufacturing.

Presented herein are systems and methods of producing universal and/or off-the-shelf CAR-T compositions suitable for cancer therapy to be administered to one or more individuals. A CAR-T composition is a composition comprising one or more types of chimeric antigen receptor T cells (CAR-T). The iPSCs and/or cell lines, and any iPSC-derived CAR-T compositions derived therefrom, are identified as compatible with one or more individuals using an identification of a cell type indicative of compatibility (e.g., HLA match and/or ABO blood match and/or RHD blood match). The compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a donor. The retrieved compatible cells are then used to derive iPSC-derived CAR-T compositions, wherein the derived compositions are suitable for therapy of one or more individuals.